What is B. Riley’s Forecast for CRBP Q1 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Equities researchers at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued on Thursday, March 13th. B. Riley analyst K. Patel expects that the biopharmaceutical company will post earnings per share of ($0.92) for the quarter. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($0.92) EPS and Q3 2025 earnings at ($0.92) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.24.

CRBP has been the subject of several other reports. Wedbush reiterated an “outperform” rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a research note on Wednesday. Jefferies Financial Group reduced their target price on Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating for the company in a research note on Tuesday. Piper Sandler started coverage on Corbus Pharmaceuticals in a research note on Monday, December 2nd. They set an “overweight” rating and a $35.00 target price for the company. William Blair started coverage on Corbus Pharmaceuticals in a research note on Friday, February 28th. They set an “outperform” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 target price (down from $75.00) on shares of Corbus Pharmaceuticals in a research note on Wednesday. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Corbus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $59.13.

Corbus Pharmaceuticals Trading Up 5.8 %

Shares of NASDAQ CRBP opened at $6.79 on Friday. Corbus Pharmaceuticals has a 12 month low of $6.38 and a 12 month high of $61.90. The stock has a 50 day moving average of $9.44 and a 200-day moving average of $18.99. The company has a market capitalization of $82.70 million, a P/E ratio of -1.45 and a beta of 2.63.

Institutional Trading of Corbus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Vestcor Inc acquired a new stake in Corbus Pharmaceuticals during the 3rd quarter worth approximately $64,000. JPMorgan Chase & Co. raised its holdings in Corbus Pharmaceuticals by 27.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 1,172 shares in the last quarter. MetLife Investment Management LLC acquired a new position in Corbus Pharmaceuticals in the 3rd quarter valued at $123,000. Wells Fargo & Company MN raised its holdings in Corbus Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 2,195 shares in the last quarter. Finally, Avanza Fonder AB acquired a new position in Corbus Pharmaceuticals in the 4th quarter valued at $84,000. 64.64% of the stock is owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.